Longwood launches Immunitas with $39M and single-cell genomics platform

Immunitas is harnessing single-cell analysis to identify new immune targets for cancer

With $39M series A, Immunitas is harnessing single-cell analysis to identify new immune targets for cancer.

Immunitas Therapeutics emerged from stealth mode on Thursday with a $39 million series A round and a single-cell genomics platform to identify novel targets for mAbs that boost antitumor immunity.

Momentum is growing around use of single-cell analysis and human tissue samples, rather than animal models, to

Read the full 621 word article

User Sign In